{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-028621","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.242456+00:00","generated_at":"2026-06-13T22:55:47.896644+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Arcus Biosciences annual meeting results and revised director comp: $45k retainer, $750k initial equity","bullets":["All four director nominees elected; Ernst & Young ratified as auditor; say-on-pay approved with ~92% for.","Board revised non-employee director compensation: annual cash retainer $45,000; additional committee chair retainers up to $25,000.","Initial equity award ~$750,000 (2/3 options, 1/3 RSUs) with 3-year vesting; annual award ~$400,000 with 12-month or next meeting vesting.","Compensation changes effective June 15, 2023, as detailed in Exhibit 10.1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-028621","json":"https://secwatch.observer/filing/0000950170-23-028621.json","markdown":"https://secwatch.observer/filing/0000950170-23-028621.md","text":"https://secwatch.observer/filing/0000950170-23-028621.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/rcus-20230615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:55:47.896644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ad770986ca47aea4c79f293ccb8bba8b5c4ff93","claim":"Arcus Biosciences, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2023-06-15 meeting.","evidence_excerpt":"Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 56,058,305 2,350,776 50,777 8,655,281","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"5d063021f1449a4004cd6e0749f6c066cc4421f7","claim":"Arcus Biosciences, Inc. shareholders approved Election of directors at the 2023-06-15 meeting.","evidence_excerpt":"Proposal 1 : The election of a director to hold office until the 2026 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dr. David Lacey 40,854,980 17,604,878 8,655,281 Dr. Juan Jaen 43,694,709 14,765,149 8,655,281 Dr. Merdad Parsey 42,680,149 15,779,709 8,655,281 Ms. Nicole Lambert 46,262,513 12,197,345 8,655,281","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"},{"claim_id":"c66d2617bf1a78ad80bb68b33e77a7618b4117fc","claim":"Arcus Biosciences, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.","evidence_excerpt":"Proposal 2 : The ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 65,921,166 1,127,268 66,708","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023028621/0000950170-23-028621-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-15"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}